020 7713 0990

Patients with Hodgkin lymphoma which is refractory to first-line therapy, or who relapse after achieving an initial remission, can often still be treated effectively with further ('salvage') chemotherapy, which may be consolidated with stem cell transplantation in suitable patients. This guideline discusses the issues relating to patients with relapsed/refractory Hodgkin lymphoma, specifically:

1. Predicting prognosis at relapse/progression

2. Approaches to salvage chemotherapy - available regimens, choosing between them, and assessing response

3. Autologous stem cell transplantation

4. Allogeneic stem cell transplantation

5. Role of radiotherapy

The treatment of patients with previously untreated Hodgkin lymphoma is addressed in a separate guideline.

Declaration of Interests

The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.